Table 1.
Characteristics of patients
| Characteristics | |
|---|---|
| No. patients | 318 |
| Median age at diagnosis (range) (years) | 73 (46–93) |
| Median initial PSA (range) (ng/ml) | 450.3 (2.3–24913.3) |
| Gleason score sum, n (%) | |
| ≤7 | 13 (4.1) |
| 8 | 75 (23.6) |
| ≥9 | 204 (64.2) |
| undiagnosed | 26 (8.2) |
| T stage, n (%) | |
| ≤2c | 76 (23.9) |
| ≥3a | 242 (76.1) |
| N stage, n (%) | |
| positive | 207 (65.1) |
| M stage, n (%) | |
| 1b/1c | 259 (81.4)/59 (18.6) |
| EOD score, n (%) | |
| 0 | 14 (4.5) |
| 1 | 59 (18.9) |
| 2 | 92 (29.4) |
| 3 | 121 (38.7) |
| 4 | 27 (8.6) |
| location of visceral metastasis, n (%) | |
| liver | 6 (1.9) |
| lung | 53 (16.7) |
| Median baseline blood examination | |
| Hb (range) (g/dl) | 13.0 (5.5–17.0) |
| LDH (range) (U/l) | 208 (126–3896) |
| ALP (range) (U/l) | 408 (102–21417) |
| NLR (range) | 2.6 (0.73–10.34) |
| CRP (range) (mg/dl) | 0.2 (0.01–24.9) |
| CHAARTED high volume, n (%)a | 294 (92.5) |
| LATITUDE high risk, n (%)b | 292 (91.8) |
| Median progression-free survival (months) | 12.7 |
| Median overall survival (months) | 59.2 |
| Progression-free survival rate (%) | 3-yr: 23.3% |
| 5-yr: 14.1% | |
| Overall survival rate (%) | 3-yr: 69.4% |
| 5-yr: 49.2% | |
ALP, alkaline phosphatase; CRP, C-reactive protein; EOD, extent of disease; Hb, haemoglobin; LDH, lactate dehydrogenase; NLR, neutrophil-lymphocyte ratio; PSA, prostate-specific antigen.
a
Defined as the presence of visceral metastases or 4 bone lesions with ≥1 beyond the vertebral bodies and pelvis.
b
Defined as the presence of two of the three following factors: GS ≥8, ≥3 bone lesions, measurable visceral metastasis.